Correlation Between Inozyme Pharma and Indaptus Therapeutics
Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and Indaptus Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and Indaptus Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inozyme Pharma and Indaptus Therapeutics, you can compare the effects of market volatilities on Inozyme Pharma and Indaptus Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of Indaptus Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and Indaptus Therapeutics.
Diversification Opportunities for Inozyme Pharma and Indaptus Therapeutics
0.75 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Inozyme and Indaptus is 0.75. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and Indaptus Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Indaptus Therapeutics and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with Indaptus Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Indaptus Therapeutics has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and Indaptus Therapeutics go up and down completely randomly.
Pair Corralation between Inozyme Pharma and Indaptus Therapeutics
Given the investment horizon of 90 days Inozyme Pharma is expected to under-perform the Indaptus Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Inozyme Pharma is 1.95 times less risky than Indaptus Therapeutics. The stock trades about -0.26 of its potential returns per unit of risk. The Indaptus Therapeutics is currently generating about -0.06 of returns per unit of risk over similar time horizon. If you would invest 156.00 in Indaptus Therapeutics on September 15, 2024 and sell it today you would lose (56.00) from holding Indaptus Therapeutics or give up 35.9% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Significant |
Accuracy | 100.0% |
Values | Daily Returns |
Inozyme Pharma vs. Indaptus Therapeutics
Performance |
Timeline |
Inozyme Pharma |
Indaptus Therapeutics |
Inozyme Pharma and Indaptus Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Inozyme Pharma and Indaptus Therapeutics
The main advantage of trading using opposite Inozyme Pharma and Indaptus Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, Indaptus Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Indaptus Therapeutics will offset losses from the drop in Indaptus Therapeutics' long position.Inozyme Pharma vs. Puma Biotechnology | Inozyme Pharma vs. Iovance Biotherapeutics | Inozyme Pharma vs. Day One Biopharmaceuticals | Inozyme Pharma vs. Zentalis Pharmaceuticals Llc |
Indaptus Therapeutics vs. Puma Biotechnology | Indaptus Therapeutics vs. Iovance Biotherapeutics | Indaptus Therapeutics vs. Day One Biopharmaceuticals | Indaptus Therapeutics vs. Inozyme Pharma |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
CEOs Directory Screen CEOs from public companies around the world | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |